Leukemia

Laboratorio Barnafi-Krause is Live on SOPHiA DDM™

Retrieved on: 
Tuesday, April 2, 2024
Diagnosis, CLL, Leukemia, Incidence, Technical, Patient, NGS, Research, Death, GENETICS, Sophia Genetics, Unit production manager, Chronic lymphocytic leukemia, Bone marrow, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, April 2, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Laboratorio Barnafi-Krause is live on the SOPHiA DDM™ Platform. Laboratorio Barnafi-Krause, located in Chile, has implemented SOPHiA GENETICS' technology to help elevate its testing and analysis of blood cancers and diseases, including Leukemia.

Key Points: 
  • BOSTON and ROLLE, Switzerland, April 2, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Laboratorio Barnafi-Krause is live on the SOPHiA DDM™ Platform.
  • Laboratorio Barnafi-Krause, located in Chile, has implemented SOPHiA GENETICS' technology to help elevate its testing and analysis of blood cancers and diseases, including Leukemia.
  • With the SOPHiA DDM™ Platform, Laboratorio Barnafi-Krause will offer tailored NGS-based workflows that enable accurate and sensitive characterization of the complex mutational landscape associated with blood disorders.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma

Retrieved on: 
Thursday, March 28, 2024
B-cell lymphoma, Plasma, Shanghai Cancer Center, Rituximab, Apoptosis, Leukemia, International Journal of Hematology, Patient, Hospital, Doxorubicin, Vincristine, Fudan University, CC3, Standard of care, Acute myeloid leukemia, Epidemiology, Biomedical Chromatography, Prednisone, Peripheral T-cell lymphoma, PARP, National Cancer Center, Therapy, MYC, BTK, Safety, BeiGene, CDK9, Cyclophosphamide, DLBCL, Canadian International Council, MCL1, Follicular lymphoma, Pharmaceutical industry

The first patient was dosed in the trial led by prominent Henan Cancer Hospital and Fudan University Shanghai Cancer Center.

Key Points: 
  • The first patient was dosed in the trial led by prominent Henan Cancer Hospital and Fudan University Shanghai Cancer Center.
  • This study will be the first combination trial conducted by a Chinese biotech to combine CDK9 inhibitor and BTK inhibitor targeting DLBCL.
  • The trials of GFH009 treating peripheral T-cell lymphoma and acute myeloid leukemia have entered into phase II stage in China and the U.S. respectively.
  • Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025, Leukemia & Lymphoma, 2021
    3.

Academy Award® Winner Matthew McConaughey Narrates MacGillivray Freeman's 3D Documentary for IMAX® and Giant Screen Theaters "Superhuman Body: World of Medical Marvels"

Retrieved on: 
Tuesday, March 26, 2024
Citadel, First Citizens BancShares, Health, Personality, Organization, CGI, Edwards Lifesciences, Aortic stenosis, Woman, Philosophy, MIT, Patient, Social media, Dazed and Confused, 3D, Leukemia, Richard King Mellon, Life, Cardiovascular disease, Burroughs Wellcome Fund, IMAX, Dallas Buyers Club, MacGillivray Freeman Films, TAVR, Family, Human, Television, Entertainment

LOS ANGELES, March 26, 2024 /PRNewswire/ -- MacGillivray Freeman Films is pleased to announce that Academy Award®-winning actor Matthew McConaughey will narrate the company's newest 3D giant screen film, Superhuman Body: World of Medical Marvels, for release in select IMAX® and giant screen theatres starting April 12, 2024. 

Key Points: 
  • LOS ANGELES, March 26, 2024 /PRNewswire/ -- MacGillivray Freeman Films is pleased to announce that Academy Award®-winning actor Matthew McConaughey will narrate the company's newest 3D giant screen film, Superhuman Body: World of Medical Marvels, for release in select IMAX® and giant screen theatres starting April 12, 2024.
  • Matthew McConaughey narrates "Superhuman Body: World of Medical Marvels" -- hitting IMAX and giant screens April 12!
  • This film will inspire you, move you, empower you, and you'll be amazed by what your superhuman body can do."
  • "We are delighted to have the talented Matthew McConaughey add his distinctive voice to the project."

Fiocruz and Caring Cross Announce Collaboration Agreement to Enable Access to Affordable CAR-T Therapy in Brazil and Latin America

Retrieved on: 
Tuesday, March 26, 2024
Organization, HIV, Patient, DSM-IV codes, Knowledge, Ministry of Health, Leukemia, Infection, HIV/AIDS, Ministry, Lymphoma

RIO DE JANEIRO and GAITHERSBURG, Md., March 26, 2024 /PRNewswire/ -- Fundação Oswaldo Cruz (Fiocruz), a foundation from the Brazilian government's Ministry of Health, and Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to advanced medicinal cures for all patients, everywhere, today announced a collaboration to develop local manufacturing of chimeric antigen receptor (CAR)-T cell and stem cell gene therapies for oncology, infectious, and genetic diseases in Brazil, including CAR-T cell therapies for leukemia, lymphoma, and HIV infection.

Key Points: 
  • CAR-T cell therapies represent a revolutionary treatment, harnessing the body's own immune cells to precisely target and destroy infected cells.
  • Caring Cross has developed manufacturing processes that significantly decreases the material cost of manufacturing CAR-T cell therapy products.
  • The agreement with Fiocruz, exclusive to Brazil and Latin America, will not only enable affordable access of CAR-T cell therapies for the Brazilian public health system, but will allow access of critical materials and training needed to manufacture CAR-T cells for other organizations in Brazil and Latin America.
  • "Our collaboration with Fiocruz marks a significant step forward in making CAR-T cell therapies more accessible in Brazil and Latin America," said Boro Dropulić, Ph.D., Executive Director of Caring Cross.

Susan G. Komen® and Walgreens Mark 5 Years of Impact, Surpassing $37 Million in Cancer Support

Retrieved on: 
Monday, March 25, 2024
Health, Leukemia, Partnership, Patient, Research, Breast, Cancer, Equity, LLS, Social, Breast cancer, Nursing

CHICAGO, March 25, 2024 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization and Walgreens announced today another milestone in the transformative five-year collaboration that has not only propelled groundbreaking research in breast cancer but has also significantly expanded access to essential breast health and breast cancer services, support and resources.. Throughout this multi-year partnership, Walgreens has contributed nearly $38 million to Komen and the Leukemia & Lymphoma Society to advance research for challenging-to-treat cancers and promote equitable access to care.

Key Points: 
  • With Walgreens' support, Susan G. Komen began serving patients directly through Komen's Patient Care Center in 2020, providing services like patient navigation and financial assistance to breast cancer patients nationwide through a telehealth model.
  • During the February 2024 "Care in Your Corner" campaign, Walgreens' customers demonstrated their generosity through in-store donations, contributing more than $5.4 million.
  • This collective effort has not only provided vital funds but has also opened new avenues for Susan G. Komen to extend support to individuals impacted by breast cancer.
  • "This year marks the culmination of five years of donations to Susan G. Komen and the Leukemia and Lymphoma Society.

Advanced Map of Human Blood Stem Cells Could Guide Highly Targeted Leukemia Care

Retrieved on: 
Thursday, March 21, 2024
Glycophorin A, B cell, Gene, Flow cytometry, Gene expression, Cell, AML, Mechanics, Patient, Biomarker, Research, RNA, Leukemia, Doctor of Philosophy, AUC, CD326, Antibody, Machine learning, Game theory, Blood, Hematology, Bone marrow, Atlas, Vaccine

CINCINNATI , March 21, 2024 /PRNewswire/ -- Thanks to an unusual application of game theory and machine learning technology, a large team of scientists led by experts at Cincinnati Children's has published the world's most detailed "atlas" of the many types of stem cells and early progenitors involved in producing human blood from diverse donors.

Key Points: 
  • The team has identified more than 80 distinct subsets of hematopoietic stem and progenitor cells (HSPCs) – early-stage cells that kick off production of mature red cells, white cells and other elements of our complex blood system.
  • Among the team's key findings:
    Mixing a new "cocktail" of 132 antibodies that can target surface proteins on HSPCs and related cells.
  • Testing demonstrated that the new mix outperforms commercial products for profiling human bone marrow cells.
  • One of the most immediate potential applications of the new stem cell atlas centers on how treatment centers monitor patients receiving therapies for leukemia.

Celebree School Raises $215,000 for Children's Hospitals Across the Country

Retrieved on: 
Monday, March 18, 2024
Culture, McDonald House, Leukemia, Partnership, Education, Research, Disability studies, Child, Infant, University, Charitable organization, UMMS, Aftercare, Kennedy Krieger Institute, Entrepreneurship, Curriculum, Social skills, Helsinki University Central Hospital, Parent, School, Toy

BALTIMORE, March 18, 2024 /PRNewswire/ -- Celebree School, a leader in early childhood education that provides infant and toddler care, preschool, before and aftercare, and summer camp programs, announced a record-breaking philanthropic year, with over $215,000 raised and donated to medical centers across the country that support children of all ages. The donation amount represents the collective fundraising efforts of Celebree, Caliday, and the Huffman Family foundation.  

Key Points: 
  • With philanthropic efforts at the forefront of Celebree School's focus, thousands of children will receive medical care and support from the contributions.
  • Celebree franchisee, Kate Mulcahy matched the Celebree School Enterprise donation of $10,000 to the Children's National Hospital, leading to a donation of $20,000.
  • In Boston, Celebree School donated $12,500 to the Boston's Children Hospital for a charity event where the team was able to tour the hospital with Celebree School franchisees, Nick and Nikki Foundas.
  • In 2024 Celebree School aims to beat its record of $215,000 by reaching for the total donations to exceed $225,000.

Jasper Health and The Leukemia & Lymphoma Society® (LLS) Collaborate to Support Blood Cancer Patients

Retrieved on: 
Wednesday, March 13, 2024
Quality of life, Education, Patient, LLS, Bone marrow, Leukemia & Lymphoma Society, Cancer, Leukemia, Caregiver, Birth control

This collaboration aims to provide comprehensive support and resources to blood cancer patients and their caregivers throughout their cancer experience journey.

Key Points: 
  • This collaboration aims to provide comprehensive support and resources to blood cancer patients and their caregivers throughout their cancer experience journey.
  • Jasper Health and LLS will work together to enhance access to free care navigation and support, education, and resources for blood cancer patients, ensuring that members have access to the latest information and support services tailored to their needs.
  • "We are thrilled to join forces with The Leukemia & Lymphoma Society to better serve individuals impacted by blood cancer," said Greg Orr, COO of Jasper Health.
  • "We are excited to partner with Jasper Health to expand our reach and support for blood cancer patients," said Gina Russo, Vice President of Patient Services & Strategic Partnerships for The Leukemia & Lymphoma Society.

Bringing Light to The Darkness of Cancer: BeiGene Named National Partner of Survivorship and Hope for The Leukemia & Lymphoma Society's Light The Night

Retrieved on: 
Tuesday, March 12, 2024
Diagnosis, Research, Education, Bone marrow, Leukemia, Caregiver, Light, Partnership, Darkness, Patient, Survivor, Support, Cancer, Light the Night, RYE, LLS, BeiGene, Concurrent estate, Policy, Estate (law), Pharmaceutical industry

"BeiGene is proud to expand our partnership with the Leukemia and Lymphoma Society this year as the National Presenting Sponsor of Survivorship and Hope for Light The Night," Josh Neiman, Chief Commercial Officer at BeiGene, said.

Key Points: 
  • "BeiGene is proud to expand our partnership with the Leukemia and Lymphoma Society this year as the National Presenting Sponsor of Survivorship and Hope for Light The Night," Josh Neiman, Chief Commercial Officer at BeiGene, said.
  • "LLS's Light The Night inspires communities, bringing more people out of the darkness of cancer, shining a light on survivors everywhere.
  • BeiGene has been supporting LLS's Light The Night for the past five years, and before becoming the National Presenting Sponsor of Survivorship and Hope, was a Light The Night National Sponsor in 2022 and 2023.
  • To join Light The Night and shine a light on survivorship and hope, visit www.lightthenight.org .

Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia

Retrieved on: 
Monday, March 11, 2024
BCR-ABL, MD, Obesity, FDA, Food, Acute leukemia, Safety, Leukemia, CML, TKI, Pharmaceutical industry

FOSTER CITY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for TERN-701 for the treatment of chronic myeloid leukemia (CML).

Key Points: 
  • FOSTER CITY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for TERN-701 for the treatment of chronic myeloid leukemia (CML).
  • “CML is a serious leukemia that requires chronic, life-long treatment,” said Emil Kuriakose, MD, chief medical officer of Terns.
  • Orphan drug designation for TERN-701 underscores the FDA’s recognition of the unmet need for people living with CML and Terns’ commitment to developing new treatment options.”
    FDA Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States.
  • Orphan drug status provides benefits to drug developers, including assistance in the drug development process, tax credits for clinical costs, exemptions from certain FDA fees and seven years of post-approval marketing exclusivity.